First Vaccine to Prevent Ebola Gains Approval from The European Commission

First Vaccine to Prevent Ebola Gains Approval from The European Commission

Health

The ongoing Ebola epidemic has killed more than 21,000 people. Apart from that, there are over 3,000 confirmed cases of Ebola in the Democratic Republic of Congo (DRC). Many pharmaceuticals companies, like Johnson & Johnson, Merck, are attempting to develop medication to combat the fatal disease. Reportedly, European health authorities have approved the world’s first Ebola vaccine on Monday. A green signal from the European Commission has marked a breakthrough in the journey to avoid the exposure to the deadly disease. The European Commission has adopted a recommendation to approve marketing authorization for the Merck-manufactured Ervebo vaccine.

In October, the European Medicines Academy (EMA) had suggested a conditional marketing authorization for the vaccine by the EU. So the ground for Ervebo’s approval was already set this October. In the case of conditional marketing authorizations, new drugs or medications are approved that address unmet medical needs for patients. These medicines are granted on a swift schedule than common medications. Besides, those vaccines require less clinical trial data to be collected and examined for approval.

As per the European Commission, the Ebola epidemic in West Africa began in 2014 and killed more than 11,000 people. This current epidemic in the DRC has revealed a 67% fatality rate, and the virus has infected more than 3,000 people. As a result, in July, the World Health Organization has declared Ebola a public health emergency of international concern. Still, the warning from the federal agency remains in effect. On the other hand, initial tests for Ervebo have promised the vaccine proving to be 100% effective during trials in Guinea. Even more, as a part of clinical development, the pharmaceutical giant – Merck has supplied more than 250,000 vials to the WHO. Apart from this, the company aims to start manufacturing Ervebo in Germany, in the third quarter of the upcoming year. Even more, the vaccine is under priority consideration with the US Food and Drug Administration (FDA).